Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) EBIT (2019 - 2025)

Silo Pharma (SILO) has disclosed EBIT for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 0.82% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, down 127.29% year-over-year, with the annual reading at -$1.1 million for FY2025, 127.29% down from the prior year.
  • EBIT hit $2.4 million in Q4 2025 for Silo Pharma, up from -$1.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $2.4 million in Q4 2024 to a low of -$1.2 million in Q2 2025.
  • Historically, EBIT has averaged -$450932.6 across 5 years, with a median of -$890324.5 in 2021.
  • Biggest five-year swings in EBIT: crashed 465.48% in 2021 and later soared 306.59% in 2024.
  • Year by year, EBIT stood at -$942416.0 in 2021, then surged by 222.02% to $1.1 million in 2022, then plummeted by 201.2% to -$1.2 million in 2023, then skyrocketed by 306.59% to $2.4 million in 2024, then fell by 0.82% to $2.4 million in 2025.
  • Business Quant data shows EBIT for SILO at $2.4 million in Q4 2025, -$1.2 million in Q3 2025, and -$1.2 million in Q2 2025.